However, given the limitations of the insights of the scientific investigations and the unclear treatment period that correlated with side effects and therapeutic efficiency, the data are still insufficient in terms of defining whether IFN-α could be a choice to potentiate strategies for anti-COVID-19 treatment. The gene discussed is IFNA2; the disease is COVID-19.